Healthcare M&A Timeline Flowchart: From Prep to Close, With Regulatory Clocks
A healthcare sale runs on two clocks. The deal clock takes 25 to 39 weeks from the first readiness call to signing. That range is a conservative planning sum. It adds the stages back to back, and because some stages can overlap, signing can come sooner. The range ends at signing, not at close. The regulatory clock starts when filings go in, and the longest review that applies sets the earliest close. Closing then takes 1 to 2 weeks. The agencies, not the parties, control how long a review runs, so ask your attorney about timing for your deal. What the parties control is when the review starts. With filings prepared on both sides, they can file at signing, not weeks later, which moves the start of the clock and with it the close.
This page covers sequencing: when each workstream starts, what the seller needs in hand at each gate, and what a slipped close costs in dollars. For the filings themselves, see the healthcare M&A process guide.
Data as of November 20, 2026. Sources: CMS National Health Expenditure data for 2024, PESP 2025 deal counts, the AMA 2024 Physician Practice Benchmark Survey and Damodaran's sector multiples. Each source is linked where it appears. All week ranges and worked-example dollar figures are our planning assumptions, not benchmarks of actual healthcare deal durations. Test them with your own advisors.
The seven stages of a healthcare sell-side process
Steps overlap in practice; regulatory clocks often run in parallel with confirmatory diligence.
Text version
- 1. Readiness (before going to market): Sell-side QoE, billing and coding audit, contracts and licenses cleaned up, data room built
- 2. Positioning and buyer list: Teaser, confidential information memorandum, model; PE platforms, add-on buyers, strategics, family offices
- 3. First-round bids: NDA, management materials, indications of interest; narrow to a short list
- 4. Management meetings and LOI: Site visits, second-round bids, negotiate price mechanics, rollover, earnout; sign LOI with exclusivity
- 5. Confirmatory diligence: Buyer QoE, legal, regulatory, payer and provider diligence, RWI underwriting
- 6. Regulatory reviews (if any apply): Some deals need federal or state filings before closing. Whether any apply, and how long they take, depends on the deal, so the timing comes from your healthcare attorney
- 7. Definitive agreement and close: Purchase agreement, employment and rollover documents, funds flow, escrow; post-close integration and earnout period
HealthcareInvestmentBanking.com process map
The flowchart shows the workstreams side by side. The table numbers the stages in the order they finish, and the rest of this page uses those numbers. Three events are easy to confuse. Signing is when the purchase agreement is executed. Filing is when each party that needs to file submits its notice, and that is when a review clock can start. Closing is when funds move, after every review has cleared. In the table, signing ends stage 5, filing opens stage 6, and closing is stage 7. On the midpoint calendar below, signing and filing both happen in week 32. Review clocks run from the end of week 32, and the close follows after the review period.
| Stage | Seller output | Gate to next stage | Regulatory workstream | Planning range |
|---|---|---|---|---|
| 1. Readiness | Sell-side QoE, cleaned contracts, data room | Numbers survive a buyer's QoE | Run the federal and state review screen with counsel. Map physician pay, leases and referral arrangements | 8 to 12 weeks |
| 2. Materials and buyer list | Teaser, CIM, target list | Buyer NDAs signed | Flag buyers whose existing holdings could add reviews | 3 to 5 weeks |
| 3. IOIs and management meetings | Management presentation | Shortlist of 2 to 4 bidders | Collect each bidder's state footprint, filing plan and approval calendar | 4 to 6 weeks |
| 4. LOI and exclusivity | Signed LOI | Exclusivity granted, ending at target signing | Fix the structure. Start drafting notices. Set target signing and outside dates | 2 to 4 weeks |
| 5. Diligence and definitive agreement | Signed purchase agreement, employment agreements | Purchase agreement executed, which ends stage 5 | Finish fair market value work on post-close pay. Have both sides' filings ready to submit at signing | 8 to 12 weeks |
| 6. Filings and reviews | Each filing party files. Reviews run | All reviews cleared | Each review runs from its own filing date | Set by the reviews that apply (R) |
| 7. Close | Funds flow, payer and license transitions | Wire received | Any post-close reporting | 1 to 2 weeks |
Stage 6 is a gate, not a workstream. The dates set in stages 1 and 4 decide when it ends.
Stage 1 screen: facts to collect before the first buyer call
A seller can pull these business facts together in about a week. They help counsel judge which reviews may apply.
| Fact to collect | Why it moves the timeline |
|---|---|
| Every state where the target, its MSO and each likely buyer operate | Each state with a notice law can add its own clock |
| Target revenue by state and market share in key service lines | Review exposure can turn on size and concentration |
| Legal entity chart, including MSO and professional entities | The selling and buying entities affect who files |
| Buyer type: PE platform, family office, health system or new holding company | Investor-side buyers can have filing duties of their own |
| Every physician compensation, lease and services arrangement | These need to hold up at signing. Late fixes cost weeks |
| Payer contracts with change-of-control or assignment clauses | Payer consents run on their own schedule and can hold up the close |
The counsel packet: what to hand deal counsel in weeks 2 to 8
The screen above only saves time if its results reach counsel early enough to come back before materials go out. On the midpoint calendar below, readiness runs weeks 1 to 10 and stage 2 starts in week 11. The core items are due by week 6, which gives counsel about four weeks to respond before the CIM is drafted around a structure that may change. The net proceeds comparison follows by week 8, still ahead of stage 2.
| Packet item | Who pulls it | Done by | Gate it feeds |
|---|---|---|---|
| State footprint map for the target, its MSO and each likely buyer | CFO or operations lead | Week 2 | Review screen, stage 3 bidder questions |
| Entity chart with ownership percentages and any management agreements | Controller | Week 2 | Who files, structure fixed before the LOI |
| Revenue by state and share in key service lines | CFO | Week 3 | Review screen, outside date sizing |
| Every physician compensation, lease and services agreement, with term and renewal dates | Practice administrator | Week 4 | Fair market value work finished before signing |
| Payer contracts with change-of-control or assignment clauses flagged | Revenue cycle lead | Week 5 | Consent letters drafted in stage 5 |
| Written list of open questions, one line each | Deal lead | Week 6 | Answers in hand before stage 2 |
| Net proceeds under an asset sale and an equity sale | CFO with tax advisor | Week 8 | Structure proposed in the LOI |
A late packet can push signing back. In the dermatology example below, each week of delay is worth about $34,600 of time value on the headline price. Questions about physician pay, referrals and the MSO and professional entity structure are covered in the healthcare compliance due diligence guide, and questions about federal and state transaction reviews in the healthcare M&A process guide, the HSR and state transaction notice guide and the state notice clocks chart. Take both sets of questions to your own attorney.
Where the regulatory window sits
Three planning rules hold across regimes:
- Reviews run in parallel. Each one runs from its own filing date. The longest one sets the earliest close.
- The parties control the start date, not the length. The agencies control review timing. Ask counsel what starts each clock and how long each review may run. Where a review needs filings from both sides, one unprepared party can delay the start for both. Notices drafted before signing and dates fixed in the purchase agreement start the clocks sooner. That pulls the close forward without shortening any review.
- A first look can become a longer review. Some regimes can move from a preliminary review to an extended one. The outside date needs a buffer for that.
| Finding from the stage 1 screen | Clock that usually binds | Seller action |
|---|---|---|
| Federal notice may apply, no state law flagged | Federal premerger review | Write both parties' filing dates into the purchase agreement |
| State notice law flagged | Often the state review | Draft after the LOI and file at signing |
| Buyer is a PE platform or new holding company | Possibly a buyer-side filing | Confirm in stage 3 that the bidder has its own filing plan |
| Practice operates in several states | The longest review that applies | Put every clock on one calendar |
| Extended review opened after filing | The extended review | Rely on the outside date buffer and covenant relief negotiated at signing |
| No review flagged | The deal clock | Close on diligence, consents and funds flow |
High-risk area: Healthcare deal reviews and filings
Federal and state reviews of healthcare transactions are an area where rules are strict, change often and depend on your state, structure and facts, so specific laws, thresholds and figures belong in a conversation with your attorney. Do not rely on a website, an AI tool or a friend's experience. Engage a healthcare attorney, and bring these questions to your first meeting.
Questions to ask your attorney
1. Which federal and state transaction reviews may apply to our deal, given where the target, its MSO and each likely buyer operate?
- Why ask: The review that runs longest sets the earliest close, so the answer drives the outside date and the whole post-signing calendar.
- What can go wrong: A state review found late can push the close past dates already promised to staff, lenders and payers.
- How states have handled it: Some states have health care transaction notice or review laws, and the rules can change.
2. What starts each review clock, and what may count as a complete filing from each side?
- Why ask: Path B in the worked example below only saves weeks if both sides' filings are complete and ready at signing.
- What can go wrong: A filing found incomplete, or a buyer-side filing that lags, can delay the start of a review for both parties.
3. Could the buyer's existing holdings, investors or prior acquisitions add reviews or lengthen them?
- Why ask: A PE platform or health system with nearby holdings can bring review exposure the seller cannot see from its own numbers.
- What can go wrong: A bidder that looked fastest in stage 3 may turn out to carry the longest review.
4. How should the outside date, regulatory efforts clause and termination rights be drafted to cover a possible extended review?
- Why ask: These terms decide who carries the risk if a first look becomes a longer review.
- What can go wrong: Without a buffer, the buyer may gain a walk right in the middle of a review, after months under interim covenants.
5. Do our physician compensation, lease and services arrangements need changes before signing, and how should fair market value support be documented?
- Why ask: These arrangements draw close buyer and regulator attention in healthcare deals, and fixes take weeks.
- What can go wrong: Off-market terms found in diligence can delay signing, reopen price or add special indemnities.
6. Could our MSO and professional entity structure draw added review, and should it be settled before the LOI?
- Why ask: The entity structure can affect who files and which reviews may apply.
- What can go wrong: A structure change after the LOI can restart notice drafting and push signing back by weeks.
7. What may the practice and buyer do together between signing and close while reviews run?
- Why ask: Integration planning, staffing and payer outreach often start before close, and the interim covenants need to fit the review period.
- What can go wrong: Steps taken too early can draw regulator attention or create disputes over the interim covenants.
Other topics to raise with your attorney
- Payer contract change-of-control and assignment clauses, and the order in which consents are requested
- Credentialing and enrollment under the new owner, and when that paperwork can start
- Any post-close reporting or notice obligations
- Tax and structure differences between an asset sale and an equity sale (with your tax advisor)
- Protections for any rollover equity or earnout if the close slips
Exclusivity ends at signing, the outside date covers the reviews
Exclusivity protects the buyer while it pays for diligence. It should end at signing. From signing to close, the purchase agreement protects the seller.
| Term | Where it lives | Seller's goal |
|---|---|---|
| Exclusivity period | LOI | Sized to diligence and drafting, ending at target signing |
| Outside date | Purchase agreement | Past the longest expected review, plus a buffer for an extended review |
| Regulatory efforts clause | Purchase agreement | Each party commits to file by fixed dates and answer agency requests promptly |
| Interim operating covenants | Purchase agreement | Ordinary-course limits the practice can live with for the whole review |
| Termination rights | Purchase agreement | A clear exit if the outside date passes or a regulator blocks the deal |
Run the draft through the LOI red flags checklist before signing.
What slips the deal clock, and the fix
Most lost weeks come from the deal clock, not from regulators.
| Cause of slippage | Stage it hits | Fix during readiness |
|---|---|---|
| Buyer's QoE rejects seller add-backs | 5 | Commission a sell-side QoE and document every adjustment |
| Physician agreements unsigned or off-market | 5 | Settle compensation terms and fair market value support before the LOI |
| MSO or professional entity structure changed after the LOI | 4 to 6 | Settle ownership structure before going to market |
| Buyer not ready to file at signing | 6 | Fix the buyer's filing date in the purchase agreement |
| Payer consents requested after signing | 7 | Send consent requests as soon as signing is certain |
| Credentialing and enrollment under the new owner | 7 | Start the paperwork at signing, not at clearance |
| Lease assignments and landlord consents | 5 to 7 | Pull every lease in stage 1 and flag the consent clauses |
| Working capital peg dispute | 5 | Agree the method and trailing period in the LOI |
Buyer type and what it does to the timeline
| Buyer type | Diligence pattern | What drives timing | Seller preparation |
|---|---|---|---|
| PE platform buying an add-on | Repeat template, fast | Its own filing position and integration calendar | Match your data room to its request list |
| New platform (PE leveraged buyout) | Deeper, with lender diligence | Financing and QoE | Build a lender-grade QoE |
| Health system | Board approvals, more committees | Internal governance and review exposure | Get the approval calendar in stage 3 |
| Family office | Varies with the team | Decision speed and outside advisors | Confirm the deal team and approval path early (family office buyers) |
PE add-ons dominate several specialties. The Private Equity Stakeholder Project's 2025 review found that 95% of the 149 PE-backed dental deals it tracked in 2025 were add-ons by PE-owned platforms. In our view, a platform that has run its diligence template many times can shorten stages 3 through 5, though no source cited here measures that effect. It does not shorten any regulatory review.
Two free public tools help in stages 2 and 3. SEC EDGAR full-text search lists Form D notices that private issuers file, a record of which healthcare companies have recently raised private capital. A Form D shows an offering, not a plan to buy. FINRA BrokerCheck shows the registration and disclosure history of any firm or banker you hire to run the process.
Worked example: one signing date, two drafting paths
Hypothetical. A PE-backed platform buys a multi-site physician group. Signing is week 0. R is the length of the longest review that applies to the actual deal. D is the time needed to draft that notice from scratch, assumed here at 5 weeks. The example uses no real regulatory period because R depends on the deal.
| Path A: notices drafted after signing | Path B: notices drafted between LOI and signing | |
|---|---|---|
| Complete filings received | Week 5 (0 + D) | Week 0 |
| Longest review ends | Week 5 + R | Week R |
| Earliest close, before 1 to 2 weeks of closing mechanics | Week 5 + R | Week R |
| Extra weeks under interim covenants | 5 | 0 |
Path B finishes 5 weeks earlier whatever R turns out to be. The gain equals the drafting time taken off the critical path. Path B only works if both sides are ready. If the buyer's federal filing lags by two weeks, the federal clock can start two weeks late for everyone.
- No review applies. Both paths close on the deal clock, and the drafting work costs nothing in time.
- The regulator opens an extended review of E weeks. Path B finishes at week R + E. Set the outside date at R plus any filing lag plus a buffer sized for a plausible E. Without that buffer, the buyer gets a walk right in the middle of the review.
Worked example: what a slipped close costs
Hypothetical, our arithmetic. A dermatology group with $4.0 million of adjusted EBITDA agrees to a headline price of 9.0x, or $36.0 million. The multiple, the 5% return on cash and the 5% EBITDA decline are illustrative assumptions. Every amount uses the headline price, gross of transaction fees, debt payoff and taxes. Net proceeds are lower, so the time-value cost on net proceeds is proportionally smaller.
| Cost of delay | Assumption | Arithmetic | Amount |
|---|---|---|---|
| Time value per week | 5% annual return, simple interest | $36.0M × 5% ÷ 52 | About $34,600 |
| Time value, 5-week slip (Path A vs Path B) | Same | $36.0M × 5% × 5 ÷ 52 | About $173,100 |
| Time value, 13-week (3-month) slip | Same | $36.0M × 5% × 13 ÷ 52 | $450,000 |
| Repricing if trailing EBITDA dips 5% during the interim period | Buyer reprices at the same 9.0x | $4.0M × 5% × 9.0 | $1.8 million |
The repricing line matters most. A long interim period gives the buyer time to see softer numbers and reopen price. A fixed price, a narrow material adverse change definition and a working capital peg set at signing limit that exposure. Model these terms against your deal structure before the LOI.
The 9.0x is an input, not a market quote. Public company multiples, such as those in Damodaran's EV/EBITDA table by sector, are loose context at most. Private practices price off private comparables, size and payer mix, not public multiples.
Week-by-week calendar: from first readiness call to signing
Each stage runs at the midpoint of its planning range from the stage table. Weeks are whole calendar weeks, and each stage ends at the end of its last week. The calendar shows where the deal clock lands before any review starts, and which weeks carry the most slip risk.
| Weeks | Stage (midpoint length) | Finished by the last week | Slip to watch |
|---|---|---|---|
| 1 to 10 | 1. Readiness (10 weeks) | Sell-side QoE delivered, data room open, stage 1 screen done, every physician and lease agreement pulled | Undocumented QoE add-backs |
| 11 to 14 | 2. Materials and buyer list (4 weeks) | CIM final, NDAs signed, each buyer's holdings flagged | Buyer list built without footprint data |
| 15 to 19 | 3. IOIs and management meetings (5 weeks) | Shortlist of 2 to 4 bidders, each bidder's footprint and filing plan collected | Health system approval calendar unknown |
| 20 to 22 | 4. LOI and exclusivity (3 weeks) | Signed LOI, structure fixed, notice drafting started, exclusivity tied to week 32 | Working capital method left open |
| 23 to 32 | 5. Diligence and definitive agreement (10 weeks) | Purchase agreement signed, both sides' filings ready, fair market value work done, payer consent letters drafted | Structure change after the LOI |
| End of week 32 to end of week 32 + R | 6. Filings and reviews | Filings received by the end of week 32, all reviews cleared by the end of week 32 + R | Extended review with no outside date buffer |
| 33 + R to 34 + R | 7. Close (1 to 2 weeks) | Funds flow, credentialing under way since signing | Payer consents requested late |
At the midpoints, signing lands at week 32 (10 + 4 + 5 + 3 + 10). Across the full ranges, signing falls between week 25 (8 + 3 + 4 + 2 + 8) and week 39 (12 + 5 + 6 + 4 + 12). These are signing weeks, not closing weeks. The 14-week spread sits in the deal clock. The seller's readiness work moves it most, but buyer readiness, joint diligence, counsel turnaround and third-party consents also affect it. In the dermatology example, 14 weeks at about $34,600 a week is about $484,600 of time value on the headline price ($36.0M × 5% × 14 ÷ 52), before any repricing risk.
Two adjustments keep the calendar honest:
- Add R after signing, not after launch. With no review, a midpoint deal closes in about week 33 to 34. With one, reviews clear at the end of week 32 + R. Because weeks are counted as whole calendar weeks, a 1-week close finishes in week 33 + R and a 2-week close finishes in week 34 + R, provided complete filings went in at signing.
- Re-baseline at every gate. If readiness runs to week 12, push the target signing date and the exclusivity expiry by the same two weeks before the LOI is signed, not after.
Referral arrangements, kickback risk and corporate practice questions are covered in the healthcare compliance due diligence guide.
Who is on the other side of the table: 2024 to 2026 data
The datasets below cover different populations and periods. Do not compare them with each other.
Spending behind buyer demand, 2024. Per the CMS National Health Expenditure fact sheet, US spending on physician and clinical services grew 8.1% to $1,109.7 billion in 2024. Total US health spending grew 7.2% to $5.3 trillion in 2024, 18.0% of GDP.
PE-backed healthcare deals, calendar 2025. PESP's 2025 review, built on PitchBook and LevinPro HC data, tracked 1,029 deals: 664 add-ons, 151 leveraged buyouts and 214 growth investments. They involved 420 platform companies and 708 investment firms. PESP says its count is likely an underestimate.
| 2025 PE healthcare subsector (PESP) | Deals |
|---|---|
| Dental care | 149 (95% add-ons by PE-owned platforms) |
| Outpatient care | 148 (119 add-ons) |
| Medtech | 117 |
| Behavioral health | 56 |
Per PESP, ten of the 18 platforms with the most 2025 deals were dental companies. Within the 148 outpatient care deals PESP tracked in calendar 2025, PESP's 2025 data as reported in the Becker's ASC Review article "The outpatient specialties that dominated 2025 deal activity" ranks dermatology first with 24 deals, then eye care with 22 and oncology with 9. Check these subsector counts against the current PESP report before relying on them.
Hospital and health system buyers. If a large system is bidding, collect its board calendar and its review exposure in stage 3.
Why physicians sell, 2024. In the AMA's 2024 Physician Practice Benchmark Survey, physicians who had sold their practice cited reasons that included more leverage to negotiate payment rates with payers, access to costly resources, and help managing payers' regulatory and administrative requirements.
The AMA's release on the survey covers the same findings. Help with regulatory requirements is one of the reasons sellers reported. Regulatory review then sets their closing date.
11 dates to lock before launch
- [ ] Federal and state review screen finished with counsel for every state where the target or buyer operates
- [ ] Notice drafting start date (at LOI) and target filing date (at signing)
- [ ] Both parties' filing dates written into the purchase agreement
- [ ] MSO and professional entity structure settled before the LOI
- [ ] QoE delivery date (QoE prep checklist) and data room open date
- [ ] LOI exclusivity expiry tied to the target signing date
- [ ] Outside date set past the longest review plus a buffer for an extended review
- [ ] Fair market value work on post-close compensation finished before signing
- [ ] Working capital peg and MAC definition agreed at signing
- [ ] Payer consent request and credentialing start dates
- [ ] Closing call and funds flow date
Questions owners ask
How long does a healthcare practice sale take from preparation to close?
On this page's planning ranges, signing lands 25 to 39 weeks after the first readiness call, with week 32 at the midpoints. After signing, the longest regulatory review that applies sets the earliest close, and closing mechanics add 1 to 2 weeks. If no review applies, a midpoint deal closes in about week 33 to 34. The range is a conservative planning sum of stages that can overlap.
When does federal premerger review affect a healthcare sale timeline?
Federal antitrust premerger notice applies to some deals. Where it does, the parties file and wait before closing, and the wait turns on when the agencies receive complete filings from each side, not on the signing date. The agencies control how long the wait runs and whether it is extended. Filing preparation also takes real time, so start it during diligence. Ask your attorney during readiness whether it may apply, and write both sides' filing dates into the purchase agreement.
How do state healthcare transaction notice laws change the closing date?
Some states have healthcare transaction notice or review laws, and some can open a longer review after a first look. Where one applies, it can set the earliest possible close. Whether a law applies can turn on the parties, the deal structure and where each side operates, so screen every state where the target, its MSO and the buyer operate with your attorney. Start drafting notices once the LOI fixes the structure and finish them by signing.
Should LOI exclusivity cover the regulatory waiting periods?
No. Exclusivity runs from the LOI to signing. After signing, the purchase agreement covers the period until close through its outside date, interim operating covenants, regulatory efforts clause and termination rights. If exclusivity stretches across a long review, the seller is tied to one bidder for months and that bidder has made no binding commitment. Tie exclusivity to the target signing date and put the regulatory timing in the outside date.
Sources
- CMS, National Health Expenditure fact sheet (2024 data)
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (reports PESP 2025 data, publication date not confirmed here)
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024
- AMA press release on the 2024 Physician Practice Benchmark Survey
- Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), January 2026
- SEC EDGAR full-text search
- FINRA BrokerCheck